Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 5, 2018 - Issue 1
Submit an article Journal homepage
2,681
Views
34
CrossRef citations to date
0
Altmetric
Review Article

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Celeste PorsbjergInstitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;Respiratory Research unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, DenmarkCorrespondence[email protected]
,
Charlotte UlrikInstitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark
,
Tina SkjoldDept of Respiratory Medicine, Aarhus University Hospital, Aarhus C, Denmark
,
Vibeke BackerInstitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;Respiratory Research unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, DenmarkORCID Iconhttp://orcid.org/0000-0002-7806-7219
ORCID Icon,
Birger LaerumLHL-klinikkene Bergen, Nesttun, Norway
,
Sverre LehmanDepartment of Clinical Science, University of Bergen, Bergen, Norway;Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
,
Crister JansonDepartment of Medical Sciences: Respiratory, Allergy & Sleep Research, Uppsala University, Uppsala, Sweden
,
Thomas SandstrømDepartment of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Umeå, Sweden
,
Leif BjermerDepartment of Respiratory Medicine & Allergology, Skåne University Hospital, Lund, Sweden
,
Barbro DahlenDivision of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden
,
Bo LundbäckInstitute of Medicine/Krefting Research Centre University of Gothenburg, Gothenburg, Sweden
,
Dora LudviksdottirDept. of Allergy, Respiratory Medicine and Sleep Landspitali University Hospital Reykjavik Iceland, University of Iceland, Reykjavik, Iceland
,
Unnur BjörnsdóttirDept. of Allergy, Respiratory Medicine and Sleep Landspitali University Hospital Reykjavik Iceland, University of Iceland, Reykjavik, Iceland;Faculty of Medicine, University of Iceland, Reykjavik, Iceland
,
Alan AltrajaDepartment of Pulmonary Medicine, University of Tartu and Department of Pulmponary Medicine, Tartu University Hospital, Tartu, Estonia
,
Lauri LehtimäkiFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;Allergy Centre, Tampere University Hospital, Tampere, Finland
,
Paula KauppiDepartment of Allergy, Respiratory Diseases and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
,
Jussi KarjalainenDepartment of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
&
Hannu KankaanrantaFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
 show all
Article: 1440868 | Received 02 Oct 2017, Accepted 07 Feb 2018, Published online: 06 Mar 2018

References

  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–20.
  • Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British thoracic society difficult asthma registry. Thorax. 2012;67:754–756.
  • Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4:120–129.e3.
  • Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66:910–917.
  • Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. In: Walker S, editor. Cochrane database of systematic reviews. Chichester (UK): John Wiley & Sons, Ltd; 2014. p. CD003559.
  • Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2016. DOI:10.1016/j.jaci.2016.08.008
  • Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725.
  • McDonald VM, Vertigan AE, Gibson PG. How to set up a severe asthma service. Respirology. 2011;16:900–911.
  • von Bülow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2:759–767.e2.
  • Hekking -P-PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902.
  • van der Meer A-N, Pasma H, Kempenaar-Okkema W, et al. A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use. Eur Respir J. 2016;48:726–733.
  • Global Initiative for Asthma. Global strategy for asthma and management and prevention. In: NHLBI/WHO workshop report, editor. N. H. National Institutes of Health, Lung and Blood Institute. Bethesda (MD): Medical Communication Resources, Inc; Revised 2007. http://www.ginasthma.org
  • Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–639.
  • Backer V, Sverrild A, Ulrik CS, et al. Diagnostic work-up in patients with possible asthma referred to a university hospital. Eur Clin Respir J. 2015;2:27768.
  • von Bülow A, Backer V, Bodtger U, et al. The level of diagnostic assessment in severe asthma: a nationwide real-life study. Respir Med. 2017;124:21–29.
  • Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009;3:198–206.
  • Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–224.
  • Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181:315–323.
  • Loza MJ, Djukanovic R, Chung KF, et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17:165.
  • Koczulla AR, Vogelmeier CF, Garn H, et al. New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discov Today. 2017;22:388–396.
  • Ilmarinen P, Tuomisto LE, Niemelä O, et al. Cluster analysis on longitudinal data of patients with adult-onset asthma. J Allergy Clin Immunol Pract. 2017;5:967–978.e3.
  • Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308–1321.
  • Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54–61.
  • Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11.
  • Dweik RA, Boggs PB, Erzurum SC, et al. American thoracic society documents an official ATS clinical practice guideline : interpretation of exhaled Nitric Oxide levels (F E NO) for clinical applications. Am J Resp Crit Care. 2011;184:602–615.
  • Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol. 2015;135:822–4.e2.
  • Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.
  • Telenga ED, Kerstjens HAM, Ten Hacken NHT, et al. Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. BMC Pulm Med. 2013;13:58.
  • Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60:455–468.
  • Baarnes CB, Hansen AV, Ulrik CS. Enrolment in an asthma management program during pregnancy and adherence with inhaled corticosteroids: the ‘management of asthma during pregnancy’ program. Respiration. 2016;92:9–15.
  • Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180:817–822.
  • Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57:880–884.
  • Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.
  • Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet (London, England). 2006;368:780–793.
  • Sanchis J, Gich I, Pedersen S. Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150:394–406.
  • Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181:566–577.
  • Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;1:CD001117.
  • Ulrik CS, Claudius BK, Tamm M, et al. Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. Clin Respir J. 2009;3:161–168.
  • Sekiya K, Taniguchi M, Fukutomi Y, et al. Age-specific characteristics of inpatients with severe asthma exacerbation. Allergol Int. 2013;62:331–336.
  • Gergen PJ. Togias A. Inner City Asthma. Immunol Allergy Clin North Am. 2015;35:101–114.
  • Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997;336:1356–1363.
  • Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol. 1995;95:955–961.
  • DALES RE, Cakmak S, BURNETT RT, et al. Influence of ambient fungal spores on emergency visits for asthma to a regional children’s hospital. Am J Respir Crit Care Med. 2000;162:2087–2090.
  • Djukanović R, Feather I, Gratziou C, et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax. 1996;51:575–581.
  • Mackay D, Haw S, Ayres JG, et al. Smoke-free legislation and hospitalizations for childhood asthma. N Engl J Med. 2010;363:1139–1145.
  • Thomson NC. Asthma and smoking-induced airway disease without spirometric COPD. Eur Respir J. 2017;49:1602061.
  • Comhair SAA, Gaston BM, Ricci KS, et al. Detrimental effects of environmental tobacco smoke in relation to asthma severity. PLoS One. 2011;6:e18574.
  • Tommola M, Ilmarinen P, Tuomisto LE, et al. The effect of smoking on lung function: a clinical study of adult-onset asthma. Eur Respir J. 2016;48:1298–1306.
  • Kauppi P, Kupiainen H, Lindqvist A, et al. Long-term smoking increases the need for acute care among asthma patients: a case control study. BMC Pulm Med. 2014;14:119.
  • Fu -J-J, Gibson PG, Simpson JL, et al. Longitudinal changes in clinical outcomes in older patients with asthma, COPD and Asthma-COPD overlap syndrome. Respiration. 2014;87:63–74.
  • Tommola M, Ilmarinen P, Tuomisto LE, et al. Differences between asthma–COPD overlap syndrome and adult-onset asthma. Eur Respir J. 2017;49:1602383.
  • Hoy RF, Abramson MJ, Sim MR. Work related asthma - diagnosis and management. Aust Fam Physician. 2010;39:39–42.
  • Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30:407–413.
  • Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur Respir J. 2000;16:432–436.
  • Eriksson J, Ekerljung L, Bossios A, et al. Aspirin-intolerant asthma in the population: prevalence and important determinants. Clin Exp Allergy. 2015;45:211–219.
  • Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68:1219–1232.
  • Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145:779–786.
  • Odeh M, Oliven A, Bassan H. Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract. 1991;32:97–98.
  • Tay TR, Radhakrishna N, Hore-Lacy F, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21:1384–1390.
  • Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71:339–346.
  • Schleich F, Brusselle G, Louis R, et al. ScienceDirect Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108:1723–1732.
  • ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109:621–626.
  • Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107:73–80.
  • Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12.
  • McDonald VM, Gibson PG. ?To define is to limit?: perspectives on asthma?COPD overlap syndrome and personalised medicine. Eur Respir J. 2017;49:1700336.
  • Porsbjerg C, Lange P, Ulrik CS. Lung function in adult onset asthma. Lung function impairment increases with age at diagnosis in adult onset asthma Lung function in adult onset asthma. Respir Med. 2015:109(7):821–827.
  • Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol. 2015;136:1295–301.e1–5.
  • Mosen DM, Schatz M, Magid DJ, et al. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol. 2008;122:507–511.e6.
  • Boulding R, Stacey R, Niven R, et al. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev. 2016;25:287–294.
  • Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology. 2017;22:651–661.
  • de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016;2. DOI:10.1183/23120541.00100-2015
  • Vansteenkiste J, Rochette F, Demedts M. Diagnostic tests of hyperventilation syndrome. Eur Respir J. 1991;4:393–399.
  • Forrest LA, Husein T, Husein O. Paradoxical vocal cord motion: classification and treatment. Laryngoscope. 2012;122:844–853.
  • Low K, Lau KK, Holmes P, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med. 2011;184:50–56.
  • Traister RS, Fajt ML, Landsittel D, et al. A novel scoring system to distinguish vocal cord dysfunction from asthma. J Allergy Clin Immunol Pract. 2014;2:65–69.
  • Halvorsen T, Walsted ES, Bucca C, et al. Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement. Eur Respir J. 2017;50:1602221.
  • Luyster FS, Strollo PJ, Holguin F, et al. Association between insomnia and asthma burden in the Severe Asthma Research Program (SARP) III. Chest. 2016;150:1242–1250.
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
  • Whelan-Goodinson R, Ponsford J, Schönberger M. Validity of the hospital anxiety and depression scale to assess depression and anxiety following traumatic brain injury as compared with the structured clinical interview for DSM-IV. J Affect Disord. 2009;114:94–102.
  • Teodorescu M, Broytman O, Curran-Everett D, et al. Obstructive sleep apnea risk, asthma burden, and lower airway inflammation in adults in the Severe Asthma Research Program (SARP) II. J Allergy Clin Immunol Pract. 2015;3:566–575.e1.
  • Lee SJ, Kang HW, Lee LH. The relationship between the Epworth sleepiness scale and polysomnographic parameters in obstructive sleep apnea patients. Eur Arch Oto-Rhino-Laryngology. 2012;269:1143–1147.
  • Chiu H-Y, Chen P-Y, Chuang L-P, et al. Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-analysis. Sleep Med Rev. 2016. DOI:10.1016/j.smrv.2016.10.004
  • Patil SP, Schneider H, Schwartz AR, et al. Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest. 2007;132:325–337.
  • Miller MK, Lee JH, Miller DP, et al., TENOR Study Group. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007;101:481–489.
  • Gunnbjörnsdóttir MI, Omenaas E, Gíslason T, et al. Obesity and nocturnal gastro-oesophageal reflux are related to onset of asthma and respiratory symptoms. Eur Respir J. 2004;24:116–121.
  • Sin DD, Jones RL, Man SFP. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med. 2002;162:1477–1481.
  • Rodrigo GJ, Plaza V. Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study. Chest. 2007;132:1513–1519.
  • Liang B, Yi Q, Feng Y. Association of gastroesophageal reflux disease with asthma control. Dis Esophagus. 2013;26:794–798.
  • Boulet L-P. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897–906.
  • Naik RD, Vaezi MF. Extra-esophageal gastroesophageal reflux disease and asthma: understanding this interplay. Expert Rev Gastroenterol Hepatol. 2015;9:969–982.
  • Bisaccioni C, Aun MV, Cajuela E, et al. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics. 2009;64:769–773.
  • Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest. 2009;136:1521–1528.
  • Oguzulgen IK, Kervan F, Ozis T, et al. The impact of bronchiectasis in clinical presentation of asthma. South Med J. 2007;100:468–471.
  • Kang HR, Choi G-S, Park SJ, et al. The effects of bronchiectasis on asthma exacerbation. Tuberc Respir Dis (Seoul). 2014;77:209.
  • Truong T. The overlap of bronchiectasis and immunodeficiency with asthma. Immunol Allergy Clin North Am. 2013;33:61–78.
  • Greenberger PA, Bush RK, Demain JG, et al. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2014;2:703–708.
  • Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850–873.
  • Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129:280–291.
  • Sheikh SI, Pitts J, Ryan-Wenger NA, et al. Improved quality of life of caregivers of children with asthma through guideline based management. J Asthma. 2017;54(7):768–776. .
  • Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1.
  • Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin Immunol. 2014;134:1260–1268.e3.
  • Chan AHY, Stewart AW, Harrison J, et al. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir Med. 2015;3:210–219.
  • Levy ML, Thomas M, Small I, et al. Summary of the 2008 BTS/SIGN British Guideline on the management of asthma. Prim Care Respir J. 2009;18(Suppl 1:):S1–16.
  • Sauni R, Verbeek JH, Uitti J, et al. Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. In: Sauni R, editor. Cochrane database of systematic reviews. Chichester (UK): John Wiley & Sons, Ltd; 2015. p. CD007897.
  • Boyle RJ, Pedroletti C, Wickman M, et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax. 2012;67:215–221.
  • Westergaard CG, Porsbjerg C, Backer V. The effect of smoking cessation on airway inflammation in young asthma patients. Clin Exp Allergy. 2014;44:353–361.
  • GINA. 2017 GINA report, global strategy for asthma management and prevention [Webpages]. 2017 Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
  • Keith PK, Koch C, Djandji M, et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J. 2009;16(Suppl A):17A–31A.
  • Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.
  • O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–136.
  • Kupczyk M, Haque S, Middelveld RJM, et al. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med. 2013;107:1521–1530.
  • Yalcin AD. An overview of the effects of anti-IgE therapies. Med Sci Monit. 2014;20:1691–1699.
  • Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy. Ann Intern Med. 2011;154:573.
  • Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316.
  • Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.
  • Odajima H, Ebisawa M, Nagakura T, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66:106–115.
  • Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2016. DOI:10.1016/j.jaci.2016.08.054
  • Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J. 2016;46:1054–1062.
  • Abraham I, Alhossan A, Lee CS, et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71:593–610.
  • Caminati M, Senna G, Guerriero M, et al. Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address. Pulm Pharmacol Ther. 2015;31:28–35.
  • Mansur AH, Srivastava S, Mitchell V, et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017;124:36–43.
  • Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol. 2014;133:937–937.e2.
  • Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
  • Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels. Chest. 2016;150:789–798.
  • Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:659–668.
  • Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322–329.
  • Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148–155.
  • Bateman ED, Goehring U-M, Richard F, et al. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016;138:142–149.e8.
  • Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma. Am J Respir Crit Care Med. 2010;181:116–124.
  • d’Hooghe JNS, ten Hacken NHT, Weersink EJM, et al. Emerging understanding of the mechanism of action of bronchial thermoplasty in asthma. Pharmacol Ther. 2018;181:101–107.
  • Radhakrishna N, Tay TR, Hore-Lacy F, et al. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med. 2016;117:166–173.
  • Adelman J, McLean C, Shaigany K, et al. The role of surgery in management of samters triad: a systematic review. Otolaryngol – Head Neck Surg. 2016;155:220–237.
  • DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2016. DOI:10.1002/lary.26391
  • Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136:1431–1440.
  • Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy. 2008;63:8–160.
  • Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy. 2006;61:737–742.
  • Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709–717.
  • Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy. 2009;64:81–84.
  • Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419.
  • Freitas DA, Holloway EA, Bruno SS, et al. Breathing exercises for adults with asthma. In: Mendonça KM, editor. Cochrane database of systematic reviews. Chichester (UK)0: John Wiley & Sons, Ltd; 2013. DOI:10.1002/14651858.CD001277.pub3
  • Thomas M, McKinley RK, Mellor S, et al. Breathing exercises for asthma: a randomised controlled trial. Thorax. 2008;64:55–61.
  • Kenn K, Balkissoon R. Vocal cord dysfunction: what do we know? Eur Respir J. 2011;37:194–200.
  • Yorke J, Adair P, Doyle A-M, et al. A randomised controlled feasibility trial of group cognitive behavioural therapy for people with severe asthma. J Asthma. 2017;54(5):543–554.
  • Weiss ST. Obesity: insight into the origins of asthma. Nat Immunol. 2005;6:537–539.
  • Gibson PG. Obesity and asthma. Ann Am Thorac Soc. 2013;10:S138–S142.
  • Dias-Junior SA, Reis M, de Carvalho-Pinto RM, et al. Effects of weight loss on asthma control in obese patients with severe asthma. Eur Respir J. 2014;43:1368–1377.
  • Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011;128:508–515.e2.
  • Jiang R-S, Liang K-L, Hsin C-H, et al. The impact of chronic rhinosinusitis on sleep-disordered breathing. Rhinology. 2016;54:75–79.
  • Serrano-Pariente J, Plaza V, Soriano JB, et al. Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea. Allergy. 2016. DOI:10.1111/all.13070
  • Gibson PG, Wlodarczyk JW, Hensley MJ, et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998;158(1):36–41.
  • Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446–1462.
  • Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–667.
  • Voskamp AL, Gillman A, Symons K, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2015;3:192–199.
  • Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003;22:478–483.
  • Gibeon D, Heaney LG, Brightling CE, et al. Dedicated severe asthma services improve health-care use and quality of life. Chest. 2015;148:870–876.
  • Kankaanranta H, Tuomisto LE, Ilmarinen P. Age-specific incidence of new asthma diagnoses in Finland. J Allergy Clin Immunol Pract. 2017;5:189–191.e3.
  • Chung KF. Asthma phenotyping: A necessity for improved therapeutic precision and new targeted therapies. J Intern Med. 2016;279:192–204.
  • O’Byrne PM, Naji N, Gauvreau GM. Severe asthma: future treatments. Clin Exp Allergy. 2012;42:706–711.
  • Agache I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy. 2012;67:835–846.
  • Taube C. Bronchial asthma: is personalized therapy on the horizon? Allergo J Int. 2014;23:246–251.
  • Williamson PA, Clearie K, Menzies D, et al. Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD. Lung. 2011;189:121–129.
  • Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. 2007;137:S1–31.
  • Robinson D, Humbert M, Buhl R, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47:161–175.
  • Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders. Curr Opin Allergy Clin Immunol. 2016;16:186–200.
  • Saude EJ, Skappak CD, Regush S, et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol. 2011;127:757–764.e6.
  • Kelly RS, Dahlin A, McGeachie MJ, et al. Asthma metabolomics and the potential for integrative omics in research and the clinic. Chest. 2017;151:262–277.
  • Boudier A, Curjuric I, Basagaña X, et al. Ten-year follow-up of cluster-based asthma phenotypes in adults. A pooled analysis of three cohorts. Am J Respir Crit Care Med. 2013;188:550–560.
  • KleinJan A. Airway inflammation in asthma: key players beyond the Th2 pathway. Curr Opin Pulm Med. 2016;22:46–52.
  • Kupczyk M, Dahlén B, Sterk PJ, et al. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy. 2014;69:1198–1204.
  • McDonald VM, Maltby S, Reddel HK, et al. Severe asthma: current management, targeted therapies and future directions-A roundtable report. Respirology. 2017;22:53–60.
  • Gibson PG, Mcdonald VM. Asthma – COPD overlap 2015: now we are six. Thorax. 2015;70(7):683–691.
  • Haldar P, Pavord ID, Shaw DE, et al. Europe PMC funders group cluster analysis and clinical asthma phenotypes. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224.
  • Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax. 2003;58:561–566.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.